PATENT CLAIM ANALYSIS

Application Number: 16202482
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-04
Patent Classification: ["424", "204100"]

Abstract:
The present technology is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

Claim (Index 21):
A method for improving the efficacy of vaccine antigens comprising the steps of:\n (a) identifying constituent T cell epitopes within a vaccine antigen which share TCR contacts with proteins derived from either the human proteome or the human microbiome; and (b) recombinantly engineering modifications to said identified T cell epitopes so as to either reduce MHC binding and/or reduce homologies between TCR contacts of said target T cell epitope and the human proteome or the human microbiome.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 98.0
- Lexical Diversity: 1.20513
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15571040', '15536857', '11802106', '14910136', '12096322']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7394109230784262
- 35 USC 102 Novelty (BERT): 0.585420603752244
- Combined Prediction Score: 0.7240118911458079
- Mean Citation Score: 380.66167
- Max Citation Score: 640.5353
- Similarity Product: 379.9296315330983

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test